Does GLP-1 Weight Loss Improve Mood During Menopause?

Two health trends are colliding at once for women in their 40s and 50s: a surge in GLP-1 medication use and the well-documented mental health turbulence of the menopause transition. Large longitudinal research, including the Study of Women's Health Across the Nation (SWAN), has shown that the risk of a first depressive episode roughly doubles during perimenopause compared with premenopause, even in women with no prior history of depression. Anxiety symptoms follow a similar pattern, often worsening as estrogen and progesterone fluctuate unpredictably before leveling out after the final period.

At the same time, millions of midlife women are starting semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for weight management, and many report feeling calmer, less preoccupied with food, and more even-tempered within weeks of starting treatment. That anecdotal pattern has pushed researchers to ask a direct question: is there a real, measurable relationship between GLP-1 medications and mood in midlife women, or is it simply the relief of easier weight management layered on top of a naturally turbulent hormonal period? The honest answer, based on current evidence, is that it's probably both — and untangling the two matters for how you manage symptoms.

The most relevant data comes from a large 2026 retrospective cohort study published in Communications Medicine, led by researchers using de-identified records from the TriNetX U.S. Collaborative Network. The study compared adults with obesity prescribed semaglutide, tirzepatide, naltrexone-bupropion, phentermine, or phentermine-topiramate between 2020 and 2025, using propensity-score matching to make the groups comparable.

Among people with type 2 diabetes, both semaglutide and tirzepatide were associated with lower hazards of anxiety disorders and depression compared with naltrexone-bupropion, along with similar protective patterns for mood disorders and cognitive complaints. Among people without diabetes, the picture was more mixed: tirzepatide was linked to a higher hazard of anxiety disorders and insomnia than semaglutide, even though both drugs still outperformed naltrexone-bupropion on these measures.

The authors were careful to flag an important limitation: this is diagnosis-code data from real-world records, not a randomized trial designed to test mood outcomes, and it cannot prove that GLP-1s directly prevent anxiety or depression. Confounding is a real possibility — people who respond well to a GLP-1 physically may also be the ones least likely to develop a new anxiety diagnosis for unrelated reasons. Still, the consistency of the pattern across a large sample is notable, and it lines up with earlier smaller studies and case-report literature suggesting a mood benefit independent of weight loss itself.

Yes — and this matters for mood because unpredictable, effort-heavy weight loss is itself a source of chronic stress for a lot of women in midlife. A 2025 post-hoc analysis of the SURMOUNT trial program, led by Dr. Beverly Tchang at NewYork-Presbyterian and Weill Cornell Medicine, examined whether tirzepatide's effectiveness changes across reproductive stages in a group of 2,542 women followed for up to 88 weeks.

The results were reassuring: weight loss was statistically comparable regardless of menopause status. In SURMOUNT-1, premenopausal women lost 26% of body weight versus 2% on placebo; perimenopausal women lost 23% versus 3%; and postmenopausal women lost 23% versus 3%. Waist circumference reductions followed the same pattern — roughly 20 to 22 centimeters versus 4 to 5 centimeters on placebo across all three groups (Tchang et al., *Obesity*, 2025).

That finding directly contradicts a common worry among midlife women — that slower metabolism and hormonal changes after menopause will blunt how well a GLP-1 works. For mood specifically, knowing that the medication is working as expected can itself reduce the frustration, self-blame, and diet-related anxiety that often compound during the menopause transition, when many women have already tried and failed with multiple weight-loss approaches. Predictable, visible progress tends to lower psychological distress on its own, independent of any direct neurochemical effect.

This is where nuance matters most. Menopausal mood symptoms — irritability, rage, anxiety, and depressive episodes — are driven substantially by fluctuating and declining estrogen, which affects serotonin and GABA signaling in the brain in ways that have nothing to do with body weight. A GLP-1 medication does not correct estrogen levels, so it's unlikely to resolve mood symptoms that are primarily hormonal in origin.

There's also a practical complication: early GLP-1 side effects like nausea, fatigue, and disrupted sleep can compound irritability that's already elevated from hot flashes and night sweats. A woman who feels physically miserable from medication titration and is also getting four hours of fragmented sleep from vasomotor symptoms may reasonably feel worse before she feels better, even if the medication is doing exactly what it's supposed to do metabolically.

This is one reason clinicians increasingly discuss hormone therapy (HRT) and GLP-1 therapy together rather than treating them as separate decisions. For women within the so-called HRT window of opportunity (generally within 10 years of the final period or under age 60), addressing the hormonal driver of mood symptoms directly — alongside a GLP-1 for weight and metabolic health — tends to produce better overall symptom control than relying on either treatment alone.

In practice, timing and pattern are your best clues. Mood changes that emerged in the first two to four weeks after starting or increasing a GLP-1 dose, especially alongside nausea, appetite loss, or fatigue, are more likely medication-related and often ease as your body adjusts. Mood symptoms that fluctuate with your menstrual cycle, worsen in the days before a period, or come with hot flashes, night sweats, and brain fog point more toward a hormonal cause.

Keeping a simple daily log — mood, sleep quality, hot flash frequency, GI symptoms, and injection day — for four to six weeks gives you and your clinician real data instead of guesswork. Several women using Lea for GLP-1 and menopause tracking have found that patterns become obvious within a few weeks: irritability that spikes the day after an injection points to the medication, while irritability that spikes regardless of injection timing but tracks with sleep loss points to menopause.

It's also worth ruling out thyroid dysfunction, which mimics both GLP-1 side effects and perimenopausal symptoms and is common enough in this age group that most clinicians will check it if mood or fatigue complaints persist.

Don't assume you have to choose between treating your weight and treating your mood, and don't stop a GLP-1 abruptly without talking to your prescriber first. Start by bringing a specific, dated symptom log to your next appointment rather than a general complaint of "feeling off." Ask directly whether hormone therapy is appropriate for you, since it's the treatment best supported by evidence for hormonally driven mood symptoms in perimenopause and early menopause.

If anxiety or depressive symptoms are significant, persistent, or affecting your ability to function, ask for a formal mental health screening (such as a PHQ-9 or GAD-7) rather than relying on how a visit "feels." These symptoms are common, real, and treatable — with therapy, medication, lifestyle changes, or a combination — and they deserve the same direct evaluation as a physical symptom. A slower dose titration, adjusted injection timing, or addressing sleep and nausea can also meaningfully change how a GLP-1 feels day to day, which often improves mood indirectly.